The aim of this study was to determine the toxicokinetics of inhaled 1,1,1,3,3-pentafluoropropane (HFC-245fa) in humans. Five healthy volunteers of each sex were exposed in random order to 0, 100, or 300 ppm HFC-245fa for 2 h at light exercise (50 W) in an exposure chamber. Capillary blood, urine, and exhaled air were sampled up to 22 h postexposure and analyzed for HFC-245fa. In addition, the metabolites fluoride, 3,3,3-trifluoropropionic acid (TFPA), and trifluoroacetic acid (TFAA) were analyzed in urine. Symptoms of irritation and central nervous system effects were rated in visual analogue scales. Various biochemical (aspartate-amino transferase, alanine-amino transferase, alkaline phosphate, glutamyl transferase, urate, creatine kinase [CK], and CK muscle brain) and inflammatory markers (serum amyloid A protein, fibrinogen, D-dimer, Creactive protein, and interleukin-6) in plasma were analyzed. The initial increase in blood was fast and an apparent steady state was reached within a few minutes at both exposure levels. The postexposure decrease in blood was equally fast and parallel to that in exhaled air. Only minor amounts of unchanged HFC-245fa were excreted in breath (0.7% of inhaled) and urine (0.001%). The observed time courses in blood and breath agreed reasonably well those obtained by physiologically based pharmacokinetic (PBPK) modeling. The PBPK simulations indicate a relative uptake during exposure of 2.1%. TFPA was not detected in urine, and no increase in TFAA or fluoride above background was seen, suggesting little or no metabolism, the calculated minimum detectable metabolism being 0.001% of the inhaled amount. The symptom ratings revealed no HFC-245fa-related effects. None of the biochemical markers was affected. The changes in inflammatory markers, some of which are statistically significant, were not consistent with an inflammatory response.
1,1,1,3,3-pentafluoropropane (HFC-245fa) is a volatile, lowboiling liquid of low toxicity. HFC-245fa is one of the major hydrofluorocarbons (HFC) that have replaced the ozonedepleting chlorofluorocarbons and hydrochlorofluorocarbons in refrigeration and air-conditioning applications. It has also been tested for anesthetic use (Kosaraju and Vandewalle, 2009) . Rusch et al. (1999) have carried out various in vivo and in vitro and toxicity studies with HFC-245fa. In summary, they found that the substance is not mutagenic and does not cause developmental toxicity. Even at high inhalation exposure concentrations (mice and rats were exposed for 4 h to 100,000 and 203,000 ppm, respectively), only mild signs of acute toxicity were seen. Rusch et al. (1999) concluded that 2000 ppm represents a no-effect level for diffuse myocarditis, that exposure below 5000 ppm gives no clear signs of toxicity, and that effects up to 50,000 ppm are mild.
Regarding biotransformation, Bayer et al. (2002) reported very low metabolic rates of HFC-245fa, both in vivo and in vitro. Trifluoroacetic acid (TFAA) and inorganic fluoride was the major urine metabolites detected after inhalation exposure of rats. No in vivo studies on the disposition of HFC-245fa in humans were found. In human liver microsomes, HFC-245fa was metabolized to TFAA (0-11.6 pmol/mg of protein/min) and 3,3,3-trifluoropropionic acid (TFPA) (0.7-7.6 pmol/mg of protein/min) by cytochrome P450. The metabolic rate was about 10 times higher in rat liver microsomes than in human ones (Bayer et al., 2002) . TFPA is highly toxic in rats with an LD 50 of 10 mg/ kg; therefore, this metabolite is of potential concern when exposing humans. Based on the human in vitro data and scaling to the whole liver, the maximum theoretical formation rate of TFPA in vivo is less than 1 lg/kg body weight and minute. This calculation is based on a protein content of 40 mg/g liver (Hakooz et al., 2006) , a liver weight of 1500 g and a body weight of 70 kg. Thus, TFPA is not likely to be produced at toxic levels.
The main objective of this study was to determine uptake, distribution, and elimination of HFC-245fa in humans during and after short-term exposure. In addition, irritative and central nervous system (CNS) symptoms were assessed using visual
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analogue scales (VAS). Since inflammatory diseases have been reported in relation to occupational exposure to HFC (Hagberg and Lillienberg, 1999; Lillienberg et al., 2002) , inflammatory markers were analyzed in plasma before and after exposure to HFC-245fa. These markers were high sensitivity C-reactive protein (CRP), serum amyloid A protein (SAA), fibrinogen, interleukin-6 (IL-6), and D-dimer. Increases in aspartate-amino transferase (ASAT), alanine-amino transferase (ALAT), alkaline phosphate (ALP), and creatine kinase (CK) were observed in rats exposed to 10,000 ppm HFC-245fa (Rusch et al., 1999) ; therefore, these biochemical markers were included. Furthermore, CK muscle brain (CK-MB) and glutamyl transferase (GT) were included as these enzymes were affected in rats after exposure to TFPA (Bayer, 2005) . Uric acid was measured as it has been shown to have contradictory antioxidant and proinflammatory properties (Feig et al., 2008) .
MATERIALS AND METHODS

Subjects
Ten volunteers, five women and five men with a mean age of 27.5 years (range 22-37 years), participated in the study. The average weight and body mass index (BMI) of the women were 66.3 kg (52.0-76.2 kg) and 22.4 (19.6-25.6 ), respectively. The corresponding values for the men were 72.8 kg (68.0-86.3 kg) and 22.6 (19.9-27 .2). The volunteers were recruited by advertisement among graduate students at Karolinska Institutet. Inclusion criteria were as follows: age 20-50 years, healthy, nonsmoker, and without chronic diseases. A medical examination, including clinical blood chemistry tests, was performed prior to inclusion in the study. To avoid fetal exposure, females performed a pregnancy test (hcG One Step Pregnancy Test, Acon Laboratories, Inc., San Diego, CA) immediately before each exposure. The subjects were informed about the design of the study, possible hazards, and their right to immediately and unconditionally interrupt the exposure. Each participant was informed orally and in writing and signed a written consent. The study was performed according to the Helsinki declaration and approved by the Regional Ethical Review Board in Stockholm.
Experimental Design
Two subjects at a time were exposed at three separate occasions to vapors of HFC-245fa (min 99.8%, provided from Honeywell International, The Netherlands) at 100 and 300 ppm and to clean air as control exposure. The subjects were exposed (whole body) for 2 h during light exercise (50 W) on computer-controlled ergometer bicycles (Monark Ergomedic 829 E, Monark Exercise AB, Vansbro, Sweden) in an exposure chamber (20 m 3 ) with a controlled climate. The target temperature and relative humidity were 18°C and 30%, respectively. The temperature was chosen to achieve a pleasant environment for light exercise and at the same time being within the normal range of indoor air temperatures at the work place. The humidity corresponds to that typically seen in indoor air in Sweden during the cold season. The actual climate conditions were continuously recorded (Vaisala HMP 36, ETM, Sweden) and logged on a personal computer in 1-min intervals. The volunteers followed different exposure sequences according to a balanced design. They were informed about the experimental design, including the exposure concentrations, but were blinded to their own exposure sequence. The exposures of each volunteer were separated by at least 1 week. The subjects were asked to abstain from all alcoholic beverages 24 h prior to and during the experiment. They had breakfast at home, without specific recommendations, before arriving to the laboratory. None was fasting.
HFC-245fa was introduced to the chamber via a preheated glass tube connected to the inlet air stream via a pressure regulator (AGA Gas AB, Sundbyberg, Sweden) and a mass flow controller (DFC 2600 digital mass flow controller with DFC utilization software, v. 1.04, Aalborg Instruments and Controls, Inc., NY). All the equipments (HFC-245fa container, pressure regulator, mass flow control unit, and stainless steel tubing) were heated to 35°C to allow stable vaporization. The HFC-245fa vapor was then mixed with clean air and dispersed into the entire exposure chamber through the ceiling. Two fans situated within the chamber further ensured an even distribution. The inlet airflow rate was lower than the outlet rate to prevent leakages from the chamber to the laboratory.
Sampling and Chemical Analyses
Chamber air. The concentration of HFC-245fa in chamber air was analyzed at 5-min intervals during exposure. Air was sampled from the upper central part of the exposure chamber and sucked through Teflon-coated tubing to the gas chromatography (GC) (Autosystem, PerkinElmer) by means of an air pump. The GC was equipped with a Poraplot Q (10.0 m, 0.32 ID, 10 lm, ChromPack no. 7550) capillary column and a flame ionization detector. Nitrogen was used as a carrier gas at a column pressure of 10 psi. The temperature of the injector was 225°C and that of the detector 250°C. The column temperature started at 140°C and was increased by 25°C/min to 190°C and then kept isothermal for 0.5 min. The Totalchrome (v. 6.2, PerkinElmer) software was used for peak integration. Calibration standards (4-352 ppm) were prepared by filling Tedlar bags (1-3 l, SKC, Inc., Eighty Four, PA) with known volumes of clean air by means of a calibrated pump (AirCheck sampler, Model 224-PCXR8, SKC, Inc.) and known amounts of HFC-245fa added by gas-tight Micro Syringes (Hamilton).
Exhaled air. Mixed exhaled air was collected once before the exposure, five times during (at 10, 30, 60, 90, and 110 min) , and seven times after the exposure (at 133, 146, 157, 173, 215, 360 min, and 22 h from the onset of exposure). The procedure is described in detail in (Nihlén et al., 1998) . The breath samples were analyzed with the same equipment and settings as used for chamber air (see above). The retention time of HFC-245fa was 1.3 min. The method error determined from 10 identically prepared samples was 6.6%. To achieve higher analytical sensitivity, exhaled air in the three last samples was adsorbed on stainless steel adsorption tubes and filled with Carbotrap (20/40 Mesh), Carbotrap C (20/40), and Carbosieve SIII (60/80) (all from Supelco). About 0.5 l of mixed exhaled air was collected on the tube for 2 min by means of an air pump (AirCheck 224-PCXR8, SKC). Duplicate samples were collected and analyzed in the afternoon after the end of exposure. Samples were desorbed (PerkinElmer Automated Thermal Desorption System ATD-400) and analyzed using the same GC system as described previously (Nihlén et al., 1998) . The thermal desorption settings were as follows: desorption oven 300°C, desorption time 5 min, valve 200°C, trap low À30°C, high 300°C, isothermal 5.0 min, line 200°C, and vial pressure 3 psi. A 25-m Poraplot Q capillary column (inner diameter [i.d.] 0.53 mm, coating 0.2 lm, ChromPack 7353) was used in the GC analysis. Nitrogen was used as carrier gas at a pressure of 10.0 psi. The injector and detector temperatures were 200°C and 250°C, respectively. The column temperature was kept at 40°C for 2 min initially, then raised to 130°C by 8°C/min, and finally kept isothermal for 10 min. The retention time of HFC-245fa was 16.9 min. Calibration standards (0.05-14.8 ppm) were prepared in Tedlar bags as described above. The method error determined from all prepared standards (n ¼ 40) was 9.4%. The detection limit and quantification, calculated from the minimum peak area by the GC integrator, was about 0.01 ppm.
Blood sampling. Venous blood (10 ml) was collected from the brachial vein in heparinized tubes (Venosafe, Terumo, Belgium) prior to exposure. These blood samples were used to prepare analytical calibration standards. Venous blood (approximately 15 ml) was further collected in two tubes before and 2 h after exposure for analysis of inflammatory and biochemical markers, as described later. These samples were centrifuged at 2700 3 g for 10 min, and plasma was frozen to À20°C for later assays.
For capillary blood sampling during exposure, the subject extended his or her hand through a hole in the chamber wall. About 1 min prior to sampling, the subject immersed his hand in hot water (approximately 40°C) to increase the blood flow and reduce the risk of sample contamination by HFC-245fa deposited on the skin. Capillary blood (200 ll) was collected in two EXPERIMENTAL EXPOSURE TO HFC-245FA 327 heparinized glass capillaries of 100 ll (Kebo AB, Sweden) from the subjects' fingertips 21 times, before, during (at 4, 7, 11, 15, 20, 32, 61, 92, and 117 min) , and until 22 h postexposure (at 122, 127, 130, 136, 142, 150, 178, 214, 271, 356 min, and 22 h) . The sample was immediately transferred to a gas-tight headspace vial (21.4 ml), which was instantaneously capped with a Teflonlined rubber septum. Blood sampling was carried out inside a box flushed with air to avoid sample contamination. The blood samples were analyzed the same day by headspace GC.
Urine sampling. Urine was sampled in glass bottles once before exposure at 2, 4, and 6 h after the onset of exposure, twice in the evening (at 9 and 13 h), and once the following morning (at 22 h). The volunteers were instructed to completely void the bladder at each occasion. The urine volume was recorded and pH was measured (Beckman 295 pH/temp/mV/ISE meter); thereafter, several portions of each sample were transferred to glass vials and stored at À20°C for later analysis of fluoride, TFAA, and TFPA. Urine sampled prior to exposure was used to prepare calibration standards for HFC-254fa.
HFC-245fa in blood and urine. HFC-245fa in blood and urine was analyzed by headspace GC (Hewlett Packard GC System, HP 6890 Series, automated headspace sampler, HP 7694, flame ionization detector, HP ChemStation integrator). The vials with blood (200 ll) and urine (2 ml) were rotated for 30 min in a warming cupboard (37°C) and then transferred to the headspace sampler and thermostated for another 20 min at 40°C prior to GC analyses. A 10-m Poraplot Q capillary column (i.d. 0.53, coating 2 lm,Varian CP7353) was used with nitrogen at a pressure of 10.3 psi as carrier. The temperatures were as follows: injector 80°C, detector 250°C, and column initial 60°C. After 1 min, the column temperature was increased by 20°C/min to 100°C, by 5°C/min to 130°C, 40°C/min till 200°C for 4.0 min, and finally 40°C/min till 40°C for 2 min. The retention time was 8.0 min. The method error, including sampling as well as GC analysis, was 4.1%, as measured from 25 duplicates collected during exposure to HFC245fa. The detection limits (defined as above) for blood and urine were about 0.02 and 0.002lM, respectively. Samples with undetectable amounts of HFC-245fa were assigned half the detection limit in the statistical calculations.
Metabolites in urine. Fluoride in urine sampled before and until 21 h postexposure was analyzed with ion-selective electrode (Beckman 295 pH/ temp/mV/ISE meter with Combined Fluoride Electrode, no. 51141 Beckman Instruments, Inc.). The detection limit (according to the manufacturer) was 1.1lM, and the analytical error was 2.5%.
For quantification of TFAA and TFPA, samples of urine were mixed with 80 ll 0.1M NaOH and 100 nmol difluoroacetic acid (DFAA) in 50 ll H 2 O as an internal standard. Samples were then taken to dryness in an evacuated desiccator containing anhydrous P 2 O 5 . The organic acids in the dried residues were converted to methyl esters by addition of 100 ll of methanol and 100 ll of concentrated (97%) sulfuric acid and heating for 1 h at 80°C in gas-tight reaction vials. Headspace samples (250 ll) were removed with a warmed (80°C) gas-tight syringe, and the concentrations of methyl esters were quantified by GC/mass spectrometry. Compounds were separated on Agilent Q-Plot fused-silica capillary column (30 m 3 0.32 mm i.d., film thickness, 20 lm) with the following conditions: linear temperature program from 100°C to 220°C with a heating rate of 15°C/min; injector and detector temperatures 250°C; helium 2 ml/min; and split injection with a split ratio of 5:1. During the chromatographic separation, the intensities of m/z 51, 59, 60, 69, 83, 111, and 142 were monitored with a dwell time of 100 ms. Retention times were 4.3 min for TFAA, 5.8 min for DFAA, and 7.0 min for TFPA. Quantification was performed relative to the content of DFAA (m/z 51) and referenced to calibration curves prepared with samples of urine containing 0-350 nmol/ml TFAA (quantified at m/z 69) or 0-15 nmol/ml TFPA (quantified at m/z 111). This method permitted the quantification of 1 nmol/ml TFAA and 1 nmol/ml of TFPA with a signal to noise ratio of 10:1. Deviations between repeatedly analyzed reference samples were < 10%, and the response of the detector was linear in the concentration ranges used.
Inflammatory and biochemical markers in blood. High-sensitivity CRP, SAA, IL-6, fibrinogen, and D-dimer were analyzed in venous blood collected from the brachial vein with vaccutainer tubes (EDTA, Venoject, Terumo) before, 3, and 22 h postexposure. The blood samples were centrifuged at 2700 3 g for 10 min, and plasma was frozen to À20°C for later assay. The analyses of CRP, IL-6, fibrinogen, and D-dimer were carried out at the Karolinska University Hospital, Stockholm, Sweden.
ASAT, ALAT, ALP, CK, CK-MB, GT, and uric acid were analyzed in plasma. The samples were collected using vaccutainer tubes (lithium heparin, Venoject, NR Terumo) before, 3, and 22 h postexposure. The blood samples were treated as described above and analyzed at Karolinska University Hospital.
Calculations
Toxicokinetic analyses. The inhaled amount was calculated as the pulmonary ventilation multiplied by the difference in HFC-254fa concentration in inhaled and exhaled air. The area under the concentration time curve (AUC) for blood, urine, and exhaled air was calculated by the trapezoidal method. The halftime of the HFC-254fa decrease in urine was calculated assuming a monoexponential decay by minimizing the residual sum of squares using Microsoft Excel Solver (v. 2003) . Pooled urine data from all 12 subjects were used since the data were insufficient for individual analysis.
Physiologically based pharmacokinetic model. A perfusion-limited physiologically based pharmacokinetic (PBPK) model was used to further examine the experimental data and to calculate the systemic uptake of HFC245fa. The PBPK parameters (compartmental volumes and blood flows and cardiac output) were calculated for each individual by allometric scaling based on body weight and height, as described in detail by Nihlén and Johanson (1999) . The parameters were also scaled to a 50-W workload. The alveolar ventilation was obtained from the cardiac output, using a ventilation-perfusion ratio of 2.01 at 50 W exercise (Malmberg et al., 1987) . The model has previously been used to simulate the time courses of HFC-134a and HFC-143a in blood and exhaled air (Gunnare et al., 2006 (Gunnare et al., , 2007 . The PBPK model code and parameters (except partition coefficients) are given by Gunnare et al. (2006) . For additional details, see Nihlén and Johanson (1999) .
Human blood:air, water:air, and oil:air partition coefficients for HFC-245fa were determined in a separate study (Ernstgård et al., 2009) . Partition coefficient for fat:blood was calculated from the partition coefficients of blood:air and oil:air, taking into account the amount of fat and water in adipose tissues. Partition coefficients for liver:blood and muscle:blood was calculated according to quantitative structure-property relationships given by Beliveau et al. (2003) . Partition coefficients for brain:blood and kidney:blood were predicted from olive:oil and saline:oil partition coefficients and the fraction of fat and water of each tissue (Meulenberg and Vijverberg, 2000) . The coefficients for lung:blood and vessel-rich groups:blood were subsequently calculated as average values of the brain:blood and kidney:blood partition coefficients (Gunnare et al., 2006) . The resulting partition coefficients are presented in Table 1 . 
Symptom Ratings
Symptom ratings were performed using a 0-100 mm VAS graded from ''not at all'' through ''hardly at all,'' ''somewhat,'' ''rather,'' ''quite,'' ''very,'' to ''almost unbearable.'' The 10 symptoms to be rated in the questionnaire were (1) ''discomfort in the eyes: burning, irritated, or running eyes''; (2) ''discomfort in the nose: burning, irritated, or runny nose''; (3) ''discomfort in the throat or airways''; (4) ''breathing difficulty''; (5) ''solvent smell''; (6) ''headache''; (7) ''fatigue''; (8) ''nausea''; (9) ''dizziness''; and (10) ''feeling of intoxication.'' The questionnaire was elaborated for vapor exposure and has been used in several similar inhalation studies performed in our laboratory (Ernstgård et al., 2002 (Ernstgård et al., , 2006a Iregren et al., 1993; Sundblad et al., 2004) . Symptom ratings were performed immediately before, during exposure (at 62 and 110 min), and after exposure (at 340 min from onset of exposure).
Statistical analyses. The nonparametric Wilcoxon test was used to test for gender differences in toxicokinetic parameters. Correlations with BMI were tested by linear regression analysis. Due to the skewed distribution of the VAS ratings, these data were analyzed by the Wilcoxon test and the post hoc test: Dunn's multiple comparisons test. Statistical comparison of objective effect measurements between exposure conditions was made on normally distributed values with repeated measures ANOVA, and Fisher's Protected Least Significant Difference (PLSD) test was used as a post hoc test. The values of IL-6, ASAT, ALAT, CK, CRP, and SAA were log transformed prior to the statistical analyses in order to achieve normality. Fibrinogen and CK-MB did not achieve normality and were analyzed by nonparametric methods (Friedman and Mann-Whitney U-test). No statistical analysis was performed on D-dimer and GT (except for mean and SD) since most of the samples were below the detection limit.
RESULTS
Exposure Chamber Conditions
The measured mean concentrations during exposure to HFC245fa were 98 and 296 ppm, respectively (Table 2) . Thus, the average concentrations were close to the target levels of 100 and 300 ppm. However, the variation was higher than in our previous exposure studies with other volatiles. The higher variability is likely due to the low boiling point of HFC-245fa of 15.3°C, creating unstable mass flow and evaporation. The measured chamber air temperature was slightly higher than the target of 18°C but varied little between exposure conditions (18.7°C, 19.0°C, and 18.6°C at 0, 100, and 300 ppm, respectively) and within experiments (SD 0.1°C). The relative humidity was the same at the three exposure conditions (34.0%, SD 0.5%; 34.0%, SD 1.4%; and 33.7%, SD 0.6%), although somewhat higher than the target humidity of 30%. Calculated from pooled data assuming a mono-exponential decrease.
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Physiological Parameters
The average pulmonary ventilation during exposure (including 50 W work on an ergometer bicycle) was 21.6 l/min (range 16.6-31.1) for females and 24.5 l/min (19.2-32.6) for males, respectively. After the exposure, it was decreased to 8.7 l/min (5.1-14.6) and 14.3 l/min (7.7-26.8), respectively. The average heart rate during exposure was 104.0 beats/min (SD 4.4) for females and 96.7 beats/min (1.4) for males, respectively.
HFC-245fa in Blood, Breath, and Urine
The initial increase in HFC-245fa in blood was fast, and average concentrations of 1.9 and 5.8lM were reached within a few minutes of exposure to 100 and 300 ppm, respectively (Fig. 1A) . The biphasic postexposure decrease in blood was fast as well, and within 4 h postexposure, the concentration was less than 3% of the steady-state level. The blood concentrations were below the detection limit the next morning. The fast decrease in exhaled air was parallel to that in blood (Fig. 1B) . The total inhaled amount of HFC-245fa was approximately 10.3 and 32.2 mmol during 100-and 300-ppm exposure, respectively ( Table 2 ). The respiratory uptake could not be experimentally determined, as inhaled and exhaled air had similar concentrations of HFC-245fa. The PBPK model prediction of respiratory excretion was in good agreement with the experimental value. It should be noted that the latter value was obtained by extrapolation from seven 2-min breath samples collected during 24 h postexposure. On average, about 1.1% of the total amount of inhaled HFC-245fa was excreted in breath after exposure.
The postexposure decrease in urine also followed that of blood and exhaled air (Fig. 1C) . The AUC of HFC-245fa in urine was 53 and 144lM min at 100 and 300 ppm of HFC245fa, respectively, indicating linear (i.e., dose proportional) kinetics. About 0.001% of the total amount inhaled was excreted in the urine within 4 h after exposure (Table 2) .
No gender differences were seen for any of the experimental toxicokinetic parameters in Table 2 .
PBPK Modeling
The time courses of HFC-245fa in blood and exhaled air were further described by a PBPK model. The observed time courses agreed well with the exhaled air and are consistent with zero metabolism (Fig. 2) . However, there were consistent discrepancies between predictions and actual blood concentrations in about half of the subjects. It should be noted that, due to the low blood:air partition coefficient of HFC-245fa, the model is highly insensitive to changes in hepatic metabolic clearance. Metabolism can thus not be ruled out by comparisons with the PBPK simulations alone. Assuming zero metabolism, the absorbed amount was estimated to 233 and 730 lmol during exposure to 100 and 300 ppm HFC-245fa, respectively (Table 2 ). This corresponds to 2.1% of the inhaled amount at both exposure concentrations. Four phases may be identified from the halftimes of the individual PBPK compartments: two fast phase of less than 1.1 min corresponding to the vessel-rich and liver compartments, one intermediate phase of about 0.5 h for the muscles, and a slow phase of about 5 h for the fat tissues ( Table 2 ). The PBPK simulations did not indicate any significant gender differences. and 5-95% confidence intervals (j) were calculated assuming log normal distribution. Times for urine samples are given as mid-times.
Metabolites in Urine
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ERNSTGÅ RD ET AL. the exposure levels (control, 100, and 300 ppm) were found. The pH in urine was in the range 4.8-7.8.
Symptoms Questionnaire
The median rating of irritation and CNS symptoms during exposure to HFC-245fa were relatively low, only occasionally exceeding the verbal label somewhat (26 mm). In general, the ratings were subject to large interindividual variation. There was no significant difference in rating of irritation symptoms between exposure to 100 or 300 ppm HFC-245fa and the control exposure. In ratings of CNS symptoms, a slight increase in headache at 2 h after the 300-ppm exposure was ) and exhaled air (s, -). Data from 10 subjects exposed to 100 and 300 ppm HFC-245fa for 2 h during light physical exercise (50 W).
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Inflammatory and Biochemical Markers
The inflammatory markers in plasma were not significantly affected by exposure to HFC-245fa (Table 3) , with the following exceptions. SAA was seemingly increased the day after exposure at 300 ppm. It changed with time (p < 0.05, repeated measures ANOVA) and with exposure (p ¼ 0.09). Furthermore, when analyzing for ''time'' and ''exposure'' separately in a post hoc test, a significant difference between exposure to 100 and 300 ppm of HFC-245fa (p < 0.05, Fisher's PLSD test) was found. A second finding was that IL-6 changed over time (p < 0.05). In this case, the post hoc test indicated no difference between the exposure levels but a significant difference between samples taken 3 and 22 h after end of exposure (p < 0.05, Fisher's PLSD test). A third finding was that fibrinogen was significantly lower 3 h after exposure to 300 ppm of HFC-245fa (p < 0.05, Friedman test) compared to before and 1 day after exposure. No effect on CRP in plasma was seen. The D-dimer concentration was below the detection limit (0.25 mg/l) in all except two subjects; hence, no statistical analyses could be performed. No exposure-related changes were observed in the biochemical samples (Table 4) . No statistical comparisons were performed for GT since most of the samples were below the detection limit (0.1 lkat/l).
DISCUSSION
In this study, the uptake and disposition of HFC-245fa in humans are described. In addition, investigation of possible irritative and CNS symptoms by questionnaires and changes in inflammatory and biochemical markers in plasma were performed. To our knowledge, this is the first study of this kind to be published for this substance.
The concentration-time profiles at 100 and 300 ppm of HFC-245fa were parallel and proportional to the exposure concentration in all three media (blood, exhaled air, and urine) (Fig. 1) . Also the AUCs in blood and urine were approximately threefold higher after exposure to 300 ppm compared to 100 ppm (Table 2 ). This indicates linear kinetics at the tested exposure levels.
The concentration-time profiles of HFC-245fa in blood, exhaled air, and urine were also similar to those of HFC-134a and HFC-143a (Gunnare et al., 2006 (Gunnare et al., , 2007 . As in the previous studies, by using the PBPK model, an estimate of the net uptake (i.e., the amount inhaled minus the amount exhaled) of HFC during exposure could be obtained. This parameter could not be determined experimentally with any accuracy, since almost similar concentrations in exhaled air and inhaled (chamber) air were measured. The similar concentrations, indicating a low respiratory uptake, were not surprising in view of the low blood:air partition coefficient of HFC-245fa of 0.62 (Table 1) .
The PBPK predictions for exhaled air postexposure and for blood during exposure agree very well with the observed time courses in most experiments, as seen in Figure 2 . Thus, there was uniformly good correspondence for exhaled breath for all a Samples (37/90) with levels below detection limit were assigned half the detection limit in the statistical calculation.
EXPERIMENTAL EXPOSURE TO HFC-245FA 333 subjects at both 100 and 300 ppm. However, some of the blood time course curves (e.g., subjects 5 and 6) were not well described by the PBPK model. In all these cases, the measured concentrations were higher than predicted and the deviations tended to appear or reach maximum around 1 h postexposure. Possible sources of the discrepancies include mix-up of samples, carryover effects in the analytical chain, and chemical losses during capillary blood sampling. Mix-up of samples is unlikely as the deviations always point in the same deviations. Moreover, we have performed numerous similar volunteer exposure studies over the year without this type of deviations. Carryover effects are unlikely since the sampled blood only passes new, previously unused glass material, a capillary tube, and a headspace vial before entering the gas chromatograph. No carryover effects were seen in the later part of the analytical chain, for example, when running a blank blood sample after a blood sample spiked to a high concentration. Chemical losses during blood sampling cannot be completely ruled out, as HFC-245fa is highly volatile and may escape from the fingertip prior to entering the capillary tube. Again, this explanation is not very likely as the deviations are only seen after and not during exposure. The low method error of 4.4% also speaks against massive, variable losses.
There did not appear to be any consistent relationship of these discrepancies with gender or BMI. The only statistically significant finding was a positive correlation between BMI and amount excreted in urine after exposure at 100 ppm but not 300 ppm (amount excreted: r 2 ¼ 0.54, p ¼ 0.02; amount excreted relative to amount inhaled: r 2 ¼ 0.69, p ¼ 0.03; AUC: r 2 ¼ 0.63, p ¼ 0.006; linear regression analysis). A similar discrepancy was noted in fitting an inhalation PBPK model to time course curves with D4 (octamethylcyclotetrasiloxane). Blood D4 concentrations after exposure remained higher than predicted; exhaled concentrations were all consistent with simulations (Andersen et al., 2001; Reddy et al., 2003) . The model fits were greatly improved by adding a second, ''deep'' blood compartment from which D4 was not available for exhalation or tissue uptake. The authors suggested that this second compartment might represent D4 partitioned into blood lipoproteins. However, no studies have been done to evaluate physiological characteristics of the compartment. If other inhalation studies were conducted with HFC-245a, it would be wise to have subjects fast or be on a standard diet to see if the discrepancies with model fits to blood concentrations would improve or if the variability between subjects would be reduced.
No formal sensitivity analysis of the PBPK model is presented for HFC-245fa since present model is very similar to that for HFC-134a presented by Gunnare et al. (2006) . In those analyses, a low sensitivity to metabolic clearance was found, indicating that the model alone is not able to determine the extension of metabolism. With no metabolism, the net uptake will obviously be zero at steady state. According to the PBPK model, however, there was still an uptake of a few percentage of the inhaled amount after 2 h of exposure. This is explained by accumulation in the fat tissues.
About 0.001% of the inhaled HFC-245fa was recovered unchanged in urine. Similarly, in our previous studies, the urinary recovery of HFC-134a was 0.002% and that of HFC143a was 0.0007% (Gunnare et al., 2006 (Gunnare et al., , 2007 . The low urinary recovery of HFC-245fa is hardly explained by evaporation losses, since all voided urine samples were immediately stored in gas-tight glass bottles until being analyzed. On the contrary, the low recovery was expected and is in agreement with the low water:air partition coefficient of 0.58 (Ernstgård et al., 2009) . Thus, the concentrations of HFC-245fa in blood and urine are similar and parallel (Fig. 1) , in agreement with partition coefficients (blood:air ¼ 0.62, water:air ¼ 0.58). Due to the low urinary recovery of HFC-245fa, this pathway was not included in the PBPK model.
The potential metabolite of HFC-245fa, TFPA, has been found to be highly toxic in rats and may be associated with the toxic effect myocarditis of HFC-245fa (Bayer et al., 2002) . The authors suggest that even though TFPA is a minor metabolite it may be a precursor of a toxic metabolite that may induce myocarditis. However, the metabolism of HFC-245fa in humans seems to be very low according to our results. Thus, no TFPA was detected in our urine samples, and no increases in TFAA or fluoride above background was seen. Considering the detection limit for TFPA of 0.1lM and assuming a urinary flow of 1 ml/min, a minimum detectable excretion of 0.1 nmol/min can be calculated. With respect to TFAA, an increase from 0.3 to 0.5lM would have been detected based on the variation in background levels. This corresponds to a detectable excretion of 0.2 nmol/min. These excretion rates are approximately 3000 times lower than the calculated uptake rate of HFC-245fa during exposure of about 6 lmol/min during the 120 min of exposure, assuming zero metabolism. The excretion of fluoride varies widely in unexposed subjects, with a SD of about 0.04 lmol/min corresponding to 0.7% of the uptake rate. Thus, any major biotransformation to fluoride would have been detected, whereas minor metabolism would not. Indication of a low biotransformation of HFC-245fa has also been shown in rats. Even after exposure to high concentrations (50,000 ppm, 6 h), only low amounts of metabolites (about 7 lmol in total corresponding 0.013% of the dose) were found (Bayer et al., 2002) . Zero or negligible metabolism was also found in our two previous human inhalation experiments with HFC-134a and HFC-143a (Gunnare et al., 2006 (Gunnare et al., , 2007 .
Very low and no exposure-related changes in irritative symptoms were found in this study. A small increase in headache after exposure to 300 ppm of HFC-245fa was seen. No other CNS symptoms were reported. These findings are supported by a study in rats where mild CNS depression was seen only after high exposures (143,000 ppm, 4 h) (Rusch et al., 1999) .
During the last decade, increasing evidence has linked inflammation to the occurrence of atherosclerosis and thrombosis.
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Inflammation markers such as fibrinogen, CRP, and SAA protein have become established risk factors for ischemic heart disease (Danesh et al., 1998 (Danesh et al., , 2000 (Danesh et al., , 2005 . Some of the inflammatory markers in plasma appeared to be affected by exposure to HFC-245fa. Thus, a significant difference in SAA between exposure to 100 or 300 ppm of HFC-245fa (p ¼ 0.009) was found. However, when omitting one subject (an outlier) at the 300-ppm exposure condition, the significance disappeared. In addition, IL-6 was significantly affected by time, but not exposure or ''time 3 exposure,'' in the repeated measures ANOVA (p ¼ 0.005), the concentrations at 3 h after exposure being higher than the next morning. This increase in the afternoon is likely explained by diurnal variation, as Vgontzas et al. (2005) showed that IL-6 peaks in the afternoon. Fibrinogen was significantly lowered after exposure to 300 ppm of HFC-245fa. This contrasts our previous findings with HFC134a and HFC-143a, where the exposures caused increased fibrinogen levels on the day after exposure.
As the metabolism of HFC-245fa is extremely restricted, no or very little metabolic activation is expected. In conclusion, the scattered changes in inflammatory markers observed in the present study may either reflect a subtle inflammatory response or a chance finding. Symptoms of inflammation among refrigeration mechanics exposed to HFC like HFC-134a and HFC-143a have been reported by Hagberg and Lillienberg (1999) and Lillienberg et al. (2002) . The symptoms may be linked to other causative agents as refrigeration mechanics are exposed to other chemicals as well.
No exposure-related changes in the biochemical markers in plasma (ASAT, ALAT, ALP, CK, CK-MB, GT, and urate) were found. They were chosen as in previous studies, in rats, increases in liver enzymes and effects on heart were seen (Rusch et al., 1999) . A common feature of most of these substances is that they respond rather rapidly to different stimuli; therefore, it should be possible to detect an exposurerelated effect even after a single exposure of short duration (Pedersen and Cohr, 1984) .
In conclusion, the present study describes for the first time the toxicokinetic behavior of HFC-245fa in humans. The kinetic profile is similar to what we have previously described for two related HFC, HFC-134a and HFC-143a. The characteristics are a very low respiratory uptake, a fast increase in blood levels within the first few minutes, and, correspondingly, a fast postexposure decrease. The profiles are proportional to the exposure concentrations, suggesting linear, first-order kinetics at least up to 300 ppm. According to the PBPK model, the profile is consistent with zero or low metabolism where the low uptake during exposure can be explained by temporary storage of HFC-245fa in adipose tissues.
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